medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 1

<< Back Next >>

Ann Hepatol 2017; 16 (1)

Association Between Hepatitis B Virus and Chronic Kidney Disease: a Systematic Review and Meta-analysis

Fabrizi F, Donato FM, Messa P

Language: English
References: 43
Page: 21-47
PDF size: 295.53 Kb.


ABSTRACT

Background. Hepatitis B virus infection and chronic kidney disease are prevalent and remain a major public health problem worldwide. It remains unclear how infection with hepatitis B virus impacts on the development and progression of chronic kidney disease. Aim. To evaluate the effect of infection with HBV on the risk of chronic kidney disease in the general population. Material and methods. We conducted a systematic review of the published medical literature to determine if hepatitis B infection is associated with increased likelihood of chronic kidney disease. We used the random effects model of DerSimonian and Laird to generate a summary estimate of the relative risk for chronic kidney disease (defined by reduced glomerular filtration rate and/or detectable proteinuria) with hepatitis B virus across the published studies. Meta-regression and stratified analysis were also conducted. Results. We identified 16 studies (n = 394,664 patients) and separate meta-analyses were performed according to the outcome. The subset of longitudinal studies addressing ESRD (n = 2; n = 91,656) gave a pooled aHR 3.87 (95% CI, 1.48; 6.25, P ‹ 0.0001) among HBV-infected patients and no heterogeneity was recorded. In meta-regression, we noted the impact of male (P = 0.006) and duration of follow- up (P = 0.007) upon the adjusted hazard ratio of incidence of chronic kidney disease (including end-stage renal disease). No relationship occurred between HBV positive status and prevalent chronic disease (n = 7, n = 109,889 unique patients); adjusted odds ratio, were 1.07 (95% CI, 0.89; 1.25) and 0.93 (95% CI, 0.76; 1.10), respectively. Conclusions. HBV infection is possibly associated with a risk of developing reduced glomerular filtration rate in the general population; no link between HBV sero-positive status and frequency of chronic kidney disease or proteinuria was noted in cross-sectional surveys.


REFERENCES

  1. Eggers P. Has the incidence of end-stage renal disease in the USA and other countries stabilized? Curr Opin Nephrol Hypertens 2011; 20: 241-5.

  2. Chacko E, Surrun S, Mubarack Sani T, Pappachan J. Chronic viral hepatitis and chronic kidney disease. Postgrad Med J 2010; 86: 486-92.

  3. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 2015; 60: 3801-13.

  4. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. J Med Virol 2016; 88: 487-97.

  5. Johnson R, Couser W. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37: 663-76.

  6. Zeng C, Chen H, Wang R, Chen Y, Zhang S, Liu L, Li L, et al. Aetiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis 2008; 52: 691-8.

  7. Deng C, Song W, Liang H, Feng C, Sheng Y, Wang M. Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells. World J Gastroenterol 2006; 12: 1752-6.

  8. Pais R, Rusu E, Zilisteanu D, Circiumaru A, Micu L, Voiculescu M, Poynard T, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. Eur J Intern Med 2015; 26: 30-6.

  9. Pawlak K, Pawlak D, Mysliwiec M. Hepatitis intensified oxidative stress, MIP-1 beta and RANTES plasma levels in uraemic patients. Cytokine 2004; 28: 197-204.

  10. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, Clarke M, (PRISMA Group). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34.

  11. Poynard T, Conn H. The retrieval of randomised clinical trials in liver diseases from the medical literature: a comparison of Medlars and manual methods. Control Clin Trials 1985; 6: 271-9.

  12. Institute OHR. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Disponible en: http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp (access date 26 Apr 2014).

  13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl. 1): S1-S266.

  14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.

  15. Petitti D. Approaches to heterogeneity in meta-analysis. Stat Med 2001; 20: 3625-33.

  16. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistencies in meta-analysis. Br Med J 2003; 327: 557-60.

  17. Lo M, Lee K, Chan N, Leung W, Ko G, Chan W, So W, et al. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetics with overt nephropathy. Diabetes Obesity Metabolism 2004; 6: 223-30.

  18. Lee J, Lin M, Chang J, Hung C, Chang J, Chen H, Yu M, et al. Hepatitis C virus infection increases risk of developing endstage renal disease using competing risk analysis. Plos One 2014; 9: e100790.

  19. Cheng A, Kong P, Wong V, So W, Chan H, Ho C, Lam C, et al. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia 2006; 49: 1777-84.

  20. Chen Y, Su Y, Li C, Wu C, Lee M. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int 2015; 87: 1030-8.

  21. Chen Y, Su Y, Li C, Hung S. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan. BMC Nephrol 2015; 16: 110.

  22. Kong X, Ma X, Su H, Xu D. Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort. Chronic Dis Transl Med 2016; 2: 55-60.

  23. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res 2008; 38: 775-83.

  24. Lee J, Lin M, Yang Y, Lu S, Chen H, Hwang S. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis 2010; 56: 23-31.

  25. Cai J, Fan X, Mou L, Gao B, Liu X, Li J, Liu L, et al. Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase. Clin J Am Soc Nephrol 2012; 7: 1561-6.

  26. Lin M, Chiu Y, Lee C, Yu H, Chen H, Wu M, Hwang S. Factors associated with CKD in the elderly and non-elderly population. Clin J Am Soc Nephrol 2013; 8: 33-40.

  27. Senghore T, Su F, Lin Y, Chu F, Yeh C. Association between hepatitis B virus infection and chronic kidney disease in university students receiving physical check-ups: a cross-sectional study. J Exp Clin Med 2013; 5: 181-6.

  28. Zeng Q, Gong Y, Dong S, Xiang H, Wu Q. Association between exposure to hepatitis B virus and chronic kidney disease in China. J Int Med Res 2014; 42: 1178-84.

  29. Su S, Lin C, Kao S, Wu C, Lu K, Lai C, Yang H, et al. Risk factors and their interaction on chronic kidney disease: a multicentre case control study in Taiwan. BMC Nephrol 2015; 16: 83.

  30. Huang J, Chuang W, Dai C, Ho C, Hwang S, Chen S, Lin Z, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Int Med 2006; 260: 255-62.

  31. Combes B, Shorey J, Barrera A, Stastny P, Eigenbrodt E, Hull A, Carter N. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971; 2: 234-7.

  32. Amet S, Bronowicki J, Thabut D, Zoulim F, Bourliere M, Math urin P, de Ledinghen V, et al. Prevalence of renal abnormalities in chronic HBV infection:the HARPE study. Liver Int 2015; 148-55.

  33. Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus mono-infection. Clin Gastroenterol Hepatol 2015; 13: 1181-8.e1.

  34. Gane E, Deray G, Liaw Y, Lim S, Lai C, Rasenack J, Wang Y, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014; 146: 138-46.

  35. Tsai M, Chen C, Tseng P, Hung C, Chiu K, Chang K, Yen Y, et al. Does nucleos(t)ide analogues treatment affect renal function in chronic hepatitis B patients who have already decreased eGFR? A longitudinal study. PLoS One 2016; 11: e0149761.

  36. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011; 55: 1235-40.

  37. Shin J, Kwon H, Jang H, Lee J, Gwak G, Huh W, Jung S, et al. Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents. Medicine 2016; 95: e2400.

  38. Wong G, Tse Y, Wong W, Yip T, Tsoi K, Chan H. Long-term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 2015; 62: 689-93.

  39. Turan I, Yapali S, Bademkiran F, Kose T, Duman S, Sozbilen M, Gunsar F, et al. Telbivudine in liver transplant recipients: renal protection does not overcome the risk of polyneuropathy and myopathy. Liver Int 2015; 21: 1066-75.

  40. Shimizu I, Kohno N, Tamaki K, Shono M, Huang H, He J, Yao D. Female hepatology: favourable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 2007; 13: 4295-305.

  41. Adinolfi L, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014; 20: 3410-7.

  42. Wang C, Chen C, Lee M, Yang H, Hsiao C. Chronic hepatitis B infection and risk of atherosclerosis-related mortality: a 17-year follow-up study based on 22,472 residents in Taiwan. Atherosclerosis 2010; 2111: 624-9.

  43. Jacurska P, Drazilova S, Fedacko J, Pella D, Janicko M. Association between hepatitis B and metabolic syndrome: current state of art. World J Gastroenterol 2016; 22: 155-64.




2020     |     www.medigraphic.com